Research
Bifidobacterium longum
44 peer-reviewed studies curated from PubMed and Semantic Scholar.
Studies
Sorted by quality and recency
andImprove Symptomatology and Neuronal Damage in Neurodegenerative Disease: A Systematic Review.
This systematic review examines the impact of Bifidobacterium longum and Bifidobacterium longum subsp. infantis, alone or in combination with other strains, on neurodegenerative diseases such as Alzheimer's and Parkinson's. The review suggests these probiotics have neuroprotective effects that may delay disease progression, though clinical trials are limited.
Efficacy of probiotics regimens for Helicobacter pylori eradication: A systematic review, pairwise, and network meta-analysis of randomized controlled trials.
This systematic review and network meta-analysis assessed the efficacy and safety of probiotics in H. pylori eradication regimens. Including probiotics, particularly Bifidobacterium longum, increased eradication rates and reduced adverse effects such as nausea, vomiting, and diarrhea.
Bifidobacterium longum BB536 is associated with improvements in gastrointestinal symptoms and odor-related metabolites in microbiota-defined subgroups of male athletes consuming a high-protein diet: exploratory randomized double‑blind placebo‑controlled trial.
Exploratory RCT of 60 male athletes consuming a high-protein diet, testing the effects of Bifidobacterium longum BB536 on gastrointestinal symptoms and odor-related metabolites. No significant differences were observed in the overall cohort, but improvements in diarrhea-related symptoms and odor-related metabolites were noted in specific microbiota-defined subgroups.
Comparative evaluation of dulaglutide alone vs. dulaglutide combined with probiotics on cardiovascular risk factors in T2DM.
RCT comparing dulaglutide alone versus dulaglutide combined with probiotics in 60 overweight/obese adults with T2DM. The intervention group showed greater improvements in glycemic control, inflammatory markers, pancreatic beta-cell function, and cardiovascular risk factors, likely through gut microbiota modulation.
Strain specific effects of probiotic supplementation on serum amino acid profiles in Alzheimer's disease: a randomized, double blind, placebo controlled trial.
This randomized, double-blind, placebo-controlled trial investigated the effects of probiotic supplementation with Lactobacillus rhamnosus HA-114 and Bifidobacterium longum R0175 on serum amino acid levels in adults with mild to moderate Alzheimer's disease. The B. longum group showed significant increases in total amino acids, BCAAs, and AAAs compared to placebo, while the L. rhamnosus group showed a significant increase in BCAAs. The findings suggest that specific probiotic strains can improve serum amino acid profiles in Alzheimer's patients.
The impact of Bifidobacterium longum CCFM1112 on chronic constipation: a randomised, double-blind, placebo-controlled study.
This randomised, double-blind, placebo-controlled study investigated the efficacy of Bifidobacterium longum CCFM1112 in treating chronic constipation in 56 volunteers. The study found that B. longum CCFM1112 significantly reduced PAC-QOL scores and improved stool consistency, while also modulating gut microbiota and metabolite levels.
Comparative efficacy of probiotic mixture Bifidobacterium longum KABP042 plus Pediococcus pentosaceus KABP041 vs. Limosilactobacillus reuteri DSM17938 in the management of infant colic: a randomized clinical trial.
RCT comparing the efficacy of Bifidobacterium longum KABP042 + Pediococcus pentosaceus KABP041 versus Limosilactobacillus reuteri DSM17938 in 112 colicky infants. The B. longum + P. pentosaceus group showed a higher response rate and greater reduction in crying and fussing time compared to the L. reuteri group over 21 days.
The Impact of Fermented Milk Products ContainingBB536 on the Gut Environment: A Randomized Double-Blind Placebo-Controlled Trial.
RCT investigating the effects of fermented milk supplemented with BB536 on fecal microbiota and metabolite compositions in healthy individuals. The BB536 group showed a significantly greater relative abundance of beneficial bacteria and increased concentrations of tryptophan and other metabolites, suggesting positive modulation of the gut environment.
The Potential Immunomodulatory Effect ofsubsp.BB536 on Healthy Adults through Plasmacytoid Dendritic Cell Activation in the Peripheral Blood.
RCT evaluating the immunomodulatory effects of BB536 on healthy adults. The study found that BB536 intake significantly increased the expression of CD86 on plasmacytoid dendritic cells, suggesting potential positive effects on immune function.
Impact of Bifidobacterium longum1714® on maternal cytokine response in peripheral blood mononuclear cells.
This double-blinded randomized-controlled trial investigated the impact of Bifidobacterium longum 1714 supplementation on maternal immune responses in pregnant women. The study found no significant differences in cytokine production by maternal PBMCs in response to PAMPs or anti-CD3/28/2 between the intervention and control groups.
A key genetic factor governing arabinan utilization in the gut microbiome alleviates constipation.
The study investigates the role of the abfA cluster in Bifidobacterium longum for treating functional constipation (FC). In a clinical trial, supplementation with abfA-cluster-carrying B. longum improved FC symptoms, increased beneficial metabolites, and enriched arabinan-utilization residents. The findings highlight the potential of genomics-directed probiotic therapies.
Usefulness of Bifidobacterium longum BB536 in Elderly Individuals With Chronic Constipation: A Randomized Controlled Trial.
RCT evaluating the effects of Bifidobacterium longum BB536 on chronic constipation in 80 elderly individuals. The primary endpoint was not significant, but significant improvements in bowel movements were observed in the BB536 group compared to placebo.
Do synbiotics really enhance beneficial synbiotics effect on defecation symptoms in healthy adults?: Randomized, double-blind, placebo-controlled trial.
This randomized, double-blind, placebo-controlled trial studied the effects of synbiotics versus probiotics on defecation symptoms in 69 healthy adults with constipation tendency. The probiotic strain Bifidobacterium longum NT improved stool condition but did not increase bowel movement frequency. Synbiotics did not enhance the beneficial effects of probiotics and may attenuate them.
[The effectiveness of a probiotic containing Bifidobacterium longum BB-46 and Enterococcus faecium ENCfa-68 in the treatment of post-infectious irritable bowel syndrome. Prospective randomized comparative study].
Prospective randomized comparative study of 62 patients with post-infectious irritable bowel syndrome (PI-IBS) evaluating the effectiveness of Bifiform, containing Bifidobacterium longum and Enterococcus faecium. The study found that including Bifiform in the treatment significantly improved clinical symptoms, restored normal intestinal microbiota, and reduced inflammation, with benefits persisting 6 months post-treatment.
Probiotic Bifidobacterium longum BB68S Improves Cognitive Functions in Healthy Older Adults: A Randomized, Double-Blind, Placebo-Controlled Trial
A randomized, double-blind, placebo-controlled trial with 60 healthy older adults investigated the effect of Bifidobacterium longum BB68S on cognitive functions. The probiotic significantly improved cognitive functions, particularly in immediate memory, visuospatial/constructional, attention, and delayed memory domains, and had beneficial effects on gut microbiota.
Putative Probiotic Strains Isolated from Kefir Improve Gastrointestinal Health Parameters in Adults: a Randomized, Single-Blind, Placebo-Controlled Study.
This randomized, single-blind, placebo-controlled study evaluated the effects of probiotic strains isolated from kefir on gastrointestinal health in 56 healthy adults. Consumption of AB-kefir reduced symptoms of abdominal pain and bloating in males and increased gut microbiota diversity in both males and females, suggesting potential benefits for gastrointestinal health.
Assessment of the safety, tolerance, and protective effect against diarrhea of infant formulas containing mixtures of probiotics or probiotics and prebiotics in a randomized controlled trial.
RCT assessing safety, tolerance, and protective effect against diarrhea of infant formulas containing probiotics and synbiotics in 284 infants. The study found equivalent weight gain and no significant differences in secondary outcomes between control and study formula groups.
Fermented cereal with specific bifidobacteria normalizes bowel movements in elderly nursing home residents. A randomized, controlled trial.
RCT assessing the effect of fermented oat drink with Bifidobacterium longum and Bifidobacterium lactis on bowel movements in 209 elderly nursing home residents. The groups receiving active products had more frequent bowel movements than the placebo group, with significant differences observed.
Probiotic viability in the gastrointestinal tract in a randomised placebo controlled trial: combining molecular biology and novel cultivation techniques.
RCT evaluating the viability of Bifidobacterium longum BB536 in the gastrointestinal tract using novel cultivation techniques and PMA-qPCR. The study confirmed the presence and resilience of B. longum BB536 in the gut after supplementation, highlighting its potential as a beneficial probiotic strain.
A clinical trial about effects of prebiotic and probiotic supplementation on weight loss, psychological profile and metabolic parameters in obese subjects.
Clinical trial involving 45 obese patients divided into three groups: diet only, prebiotics (carob), and probiotics. All groups showed significant weight loss, but only the prebiotic and probiotic groups showed significant decreases in fat mass and increases in muscle strength. The prebiotic group also showed improvements in insulinemia, HOMA-IR, and sleep quality, while the probiotic group showed a decrease in fasting blood glucose.
Efficacy and Safety of Synbiotics in Patients Undergoing Autologous Hematopoietic Stem Cell Transplantation: A Randomized, Double-blinded, Placebo-controlled Pilot Study.
This randomized, double-blinded study assessed the efficacy and safety of synbiotics, including Bifidobacterium longum and guar gum, in patients undergoing autologous hematopoietic stem cell transplantation. The synbiotic group showed shorter durations of total parenteral nutrition, grade ≥3 diarrhea, and hospital stay compared to the placebo group, with improved oral intake and quality of life regarding diarrhea and anorexia.
Effects of Bifidobacterium longum BB536 and Lactobacillus rhamnosus HN001 in IBS patients.
Crossover RCT of 25 IBS patients testing a formulation of Bifidobacterium longum BB536, Lactobacillus rhamnosus HN001, and vitamin B6. The treatment significantly improved abdominal pain, bloating, disease severity, intestinal permeability, and gut microbiota compared to placebo.
Supplementation with Bifidobacterium longum Bar33 and Lactobacillus helveticus Bar13 mixture improves immunity in elderly humans (over 75 years) and aged mice.
A randomized, double-blind, placebo-controlled trial with 98 elderly adults and aged mice evaluated the effects of a probiotic mixture of Bifidobacterium longum Bar33 and Lactobacillus helveticus Bar13. The mixture improved immune response in older adults by increasing various immune cells and natural killer activity. In aged mice, the probiotics modulated gut immune cells, increasing regulatory T cells and B cells.
Impact of ageing and a synbiotic on the immune response to seasonal influenza vaccination; a randomised controlled trial.
RCT investigating the effect of a synbiotic (Bifidobacterium longum bv. infantis CCUG 52486 and gluco-oligosaccharide) on immune response to influenza vaccination in young and older subjects. The synbiotic did not affect B or T cell responsiveness to the vaccine, though CMV seropositivity was associated with lower recall response in older subjects.
Antibiotic treatment to prevent postextraction complications: a monocentric, randomized clinical trial. Preliminary outcomes.
RCT evaluating the use of antibiotics and probiotics in preventing postextraction complications in 111 patients. The antibiotic+probiotic group showed reduced gastrointestinal side effects compared to the antibiotic-alone group, with lower incidences of intestinal distension and diarrhea.
Effect of probiotics on postoperative quality of gastric bypass surgeries: a prospective randomized trial.
This double-blind, randomized trial studied the effect of probiotics on postoperative symptomatic GI episodes in 60 patients who underwent gastric bypass surgery. Probiotics groups received Clostridium butyricum or Bifidobacterium longum, and results showed improved mGIQLI scores, indicating better quality of life and reduced GI symptoms.
Perioperative supplementation with bifidobacteria improves postoperative nutritional recovery, inflammatory response, and fecal microbiota in patients undergoing colorectal surgery: a prospective, randomized clinical trial
Prospective RCT of 60 colorectal surgery patients comparing perioperative probiotic supplementation with Bifidobacterium longum BB536 to no intervention. The probiotic group showed improved postoperative nutritional markers, reduced inflammatory response, and beneficial changes in fecal microbiota composition.
Efficacy of probiotic treatment with Bifidobacterium longum 536 for induction of remission in active ulcerative colitis: A randomized, double-blinded, placebo-controlled multicenter trial.
RCT investigating the efficacy of Bifidobacterium longum 536 (BB536) supplementation for remission induction in Japanese patients with active ulcerative colitis. 63% of patients receiving BB536 showed clinical remission at week 8, with significant decreases in UCDAI scores, Rachmilewitz endoscopic index, and Mayo subscore compared to placebo.
Chronic administration of a microencapsulated probiotic enhances the bioavailability of orange juice flavanones in humans.
The study examined the effects of Bifidobacterium longum R0175 on the bioavailability of orange juice flavanones in healthy volunteers. Chronic intake of the probiotic increased the bioavailability of flavanones, as indicated by higher urinary excretion of flavanone metabolites after 4 weeks of supplementation.
Bifidobacterium longum with fructo-oligosaccharides in patients with non alcoholic steatohepatitis.
RCT of 66 patients with non-alcoholic steatohepatitis comparing Bifidobacterium longum with fructo-oligosaccharides and lifestyle modification to lifestyle modification alone. The combination significantly reduced TNF-α, CRP, serum AST levels, HOMA-IR, serum endotoxin, steatosis, and the NASH activity index.
Bifidobacterium microbiota and parameters of immune function in elderly subjects.
Double-blind placebo-controlled study of 55 elderly subjects examining the effects of Bifidobacterium longum strains on immune function. The study found specific changes in Bifidobacterium species levels and correlations with cytokine levels, suggesting modulation of the microbiota may influence inflammatory responses.
Clinical evaluation of a new starter formula for infants containing live Bifidobacterium longum BL999 and prebiotics.
RCT evaluating a starter formula for infants containing Bifidobacterium longum BL999 and prebiotics. The formula was safe and well-tolerated, with fewer incidences of constipation and a trend toward fewer respiratory tract infections.
Nutraceutical approach for the management of cardiovascular risk - a combination containing the probiotic Bifidobacterium longum BB536 and red yeast rice extract: results from a randomized, double-blind, placebo-controlled study.
A 12-week randomized, double-blind, placebo-controlled study evaluated a nutraceutical combination containing Bifidobacterium longum BB536 and red yeast rice extract in 33 subjects with low cardiovascular risk. The treatment significantly reduced total cholesterol, LDL cholesterol, and non-HDL cholesterol, improving the atherogenic lipid profile without adverse effects.
Probiotic Bifidobacterium longum NCC3001 Reduces Depression Scores and Alters Brain Activity: A Pilot Study in Patients With Irritable Bowel Syndrome.
RCT of 44 adults with IBS and mild to moderate anxiety and/or depression, comparing Bifidobacterium longum NCC3001 to placebo for 6 weeks. The probiotic reduced depression scores and increased quality of life, with associated changes in brain activation patterns, but had no significant effect on anxiety or IBS symptoms.
Effect of multispecies probiotics on irritable bowel syndrome: a randomized, double-blind, placebo-controlled trial.
This randomized, double-blind, placebo-controlled trial investigated the efficacy of multispecies probiotics on IBS symptoms and gut microbiota alterations in 49 IBS patients. The probiotics group showed significantly higher relief of IBS symptoms and improvements in abdominal pain/discomfort and bloating compared to the placebo group. Fecal analysis indicated significant increases in certain probiotic strains in the treatment group.
Double-blind, randomised, placebo-controlled intervention trial to evaluate the effects of Bifidobacterium longum CECT 7347 in children with newly diagnosed coeliac disease.
Double-blind, randomised, placebo-controlled trial in 33 children with newly diagnosed coeliac disease evaluating Bifidobacterium longum CECT 7347. The B. longum group showed greater height percentile increases, decreased peripheral CD3+ T lymphocytes, and reduced Bacteroides fragilis group compared to placebo, suggesting potential benefits for gut health and immune modulation.
Clinical effects of probiotic Bifidobacterium longum BB536 on immune function and intestinal microbiota in elderly patients receiving enteral tube feeding.
Double-blind RCT of 45 elderly patients receiving enteral tube feeding, comparing Bifidobacterium longum BB536 supplementation to placebo over 12 weeks. BB536 intake increased bifidobacteria in fecal microbiota and modulated immune function, with a tendency to increase serum IgA and maintain NK cell activity.
Clinical trial: the microbiological and immunological effects of synbiotic consumption - a randomized double-blind placebo-controlled study in active Crohn's disease.
A randomized, double-blind placebo-controlled trial involving 35 patients with active Crohn's disease tested the effects of a synbiotic comprising Bifidobacterium longum and Synergy 1. Significant improvements in clinical outcomes were observed, with reductions in Crohn's disease activity indices and histological scores. TNF-alpha expression was reduced at 3 months, and mucosal bifidobacteria proliferated in synbiotic patients.
Effect of probiotic Bifidobacterium longum BB536 [corrected] in relieving clinical symptoms and modulating plasma cytokine levels of Japanese cedar pollinosis during the pollen season. A randomized double-blind, placebo-controlled trial.
RCT of 40 subjects with Japanese cedar pollinosis testing yogurt supplemented with Bifidobacterium longum BB536 versus placebo. BB536 yogurt significantly alleviated eye symptoms and showed trends in relieving nasal and throat symptoms. It also modulated blood parameters related to immune response.
Synbiotic therapy (Bifidobacterium longum/Synergy 1) initiates resolution of inflammation in patients with active ulcerative colitis: a randomised controlled pilot trial.
A randomized controlled pilot trial investigated the effects of a synbiotic therapy combining Bifidobacterium longum and Synergy 1 on patients with active ulcerative colitis. The treatment group showed reduced sigmoidoscopy scores, decreased mRNA levels of human beta defensins, and reduced inflammatory cytokines, indicating improved inflammation and epithelial tissue regeneration.
Effects of milk products fermented by Bifidobacterium longum on blood lipids in rats and healthy adult male volunteers.
The study investigated the effects of milk products fermented by Bifidobacterium longum strain BL1 on blood lipids in rats and humans. In rats, bifidobacterium milk significantly lowered serum total cholesterol, LDL cholesterol, and triglycerides. In humans, a significant decrease in serum total cholesterol was observed in subjects with moderate hypercholesterolemia after consuming yogurt with B. longum strain BL1.
Microbiological evaluation of jejunal aspirates and faecal samples after oral administration of bifidobacteria and lactic acid bacteria.
Double-blind placebo-controlled study on the effect of oral administration of bifidobacteria and lactic acid bacteria on gut microflora. The preparation containing Enterococcus faecium and Bifidobacterium longum significantly altered the anaerobe: aerobe ratio in faeces, indicating an impact on distal intestinal microflora.
Does yogurt enriched with Bifidobacterium longum affect colonic microbiology and fecal metabolites in health subjects?
RCT comparing the effects of yogurt enriched with Bifidobacterium longum and lactulose to conventional yogurt on fecal bacterial flora and risk indexes for colon carcinogenesis in 12 healthy volunteers. Increased excretion of bifidobacteria was observed, with elevated breath-hydrogen exhalation and accelerated mouth-to-cecum transit time during enriched yogurt consumption.
Effects of Bifidobacterium longum and Lactobacillus rhamnosus on Gut Microbiota in Patients with Lactose Intolerance and Persisting Functional Gastrointestinal Symptoms: A Randomised, Double-Blind, Cross-Over Study
A randomized, double-blind, cross-over study tested the efficacy of Bifidobacterium longum BB536 and Lactobacillus rhamnosus HN001 plus vitamin B6 in 23 lactose intolerant subjects with persistent symptoms. The treatment significantly decreased bloating and ameliorated constipation, and altered fecal microbiome composition, suggesting positive modulation of gut health.